Celularity Inc. (NASDAQ:CELUW) Short Interest Update

Celularity Inc. (NASDAQ:CELUW) was the recipient of a significant decline in short interest in January. As of January 30th, there was short interest totaling 542 shares, a decline of 84.0% from the January 15th total of 3,393 shares. Based on an average trading volume of 22,573 shares, the days-to-cover ratio is currently 0.0 days. Based on an average trading volume of 22,573 shares, the days-to-cover ratio is currently 0.0 days.

Celularity Price Performance

Shares of CELUW traded down $0.00 during trading hours on Tuesday, reaching $0.01. The stock had a trading volume of 14,850 shares, compared to its average volume of 17,066. The firm has a 50-day simple moving average of $0.02 and a 200 day simple moving average of $0.03. Celularity has a 12 month low of $0.01 and a 12 month high of $0.75.

Celularity Company Profile

Celularity, Inc is a clinical-stage biotechnology company headquartered in Florham Park, New Jersey, that specializes in the development and commercialization of allogeneic “off-the-shelf” cell therapies derived from postpartum placental cells. Leveraging a proprietary platform of placental- and umbilical-derived cells, the company seeks to deliver immune-modulatory, regenerative and anti-inflammatory treatments across oncology, immunology and other therapeutic areas. By harnessing the natural properties of placental cells, Celularity aims to overcome the limitations of autologous therapies and scale production to serve a broad patient population.

The company’s pipeline includes CYNK-001, an investigational natural killer (NK) cell therapy being evaluated for hematological malignancies and solid tumors, as well as other cell-based programs targeting viral infections and tissue repair.